头孢比普在耐甲氧西林和万古霉素中介金黄色葡萄球菌所致兔主动脉瓣心内膜炎模型中的评价。
Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus.
作者信息
Chambers Henry F
机构信息
Division of Infectious Diseases, San Francisco General Hospital, and University of California--San Francisco, Room 3400, Building 30, 1001 Potrero Ave., San Francisco, CA 94110, USA.
出版信息
Antimicrob Agents Chemother. 2005 Mar;49(3):884-8. doi: 10.1128/AAC.49.3.884-888.2005.
Abstract
Ceftobiprole is a novel broad-spectrum cephalosporin that binds with high affinity to PBP 2a, the methicillin-resistance determinant of staphylococci, and is active against methicillin- and vancomycin-resistant Staphylococcus aureus. Ceftobiprole was compared to vancomycin in a rabbit model of methicillin-resistant S. aureus aortic valve endocarditis. Ceftobiprole and vancomycin were equally effective against endocarditis caused by methicillin-resistant S. aureus strain 76, whereas ceftobiprole was more effective than vancomycin against the vancomycin-intermediate S. aureus strain HIP5836. The activity of ceftobiprole against drug-resistant strains of S. aureus warrants its further clinical development.
摘要
头孢比普是一种新型广谱头孢菌素，它与葡萄球菌的耐甲氧西林决定因子PBP 2a具有高亲和力结合，并且对耐甲氧西林和耐万古霉素的金黄色葡萄球菌具有活性。在耐甲氧西林金黄色葡萄球菌主动脉瓣心内膜炎的兔模型中，对头孢比普和万古霉素进行了比较。头孢比普和万古霉素对耐甲氧西林金黄色葡萄球菌菌株76引起的心内膜炎同样有效，而头孢比普对万古霉素中介的金黄色葡萄球菌菌株HIP5836比万古霉素更有效。头孢比普对金黄色葡萄球菌耐药菌株的活性值得进一步进行临床开发。
相似文献
1
Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus.头孢比普在耐甲氧西林和万古霉素中介金黄色葡萄球菌所致兔主动脉瓣心内膜炎模型中的评价。
Antimicrob Agents Chemother. 2005 Mar;49(3):884-8. doi: 10.1128/AAC.49.3.884-888.2005.
2
Efficacy of Telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus.替考拉宁在耐甲氧西林金黄色葡萄球菌或万古霉素中介金黄色葡萄球菌所致兔主动脉瓣心内膜炎模型中的疗效
Antimicrob Agents Chemother. 2005 Aug;49(8):3163-5. doi: 10.1128/AAC.49.8.3163-3165.2005.
3
In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model.在兔心内膜炎模型中，新型广谱头孢菌素头孢洛林（PPI-0903）与利奈唑胺和万古霉素相比，对耐甲氧西林和万古霉素中介金黄色葡萄球菌的体内疗效。
Antimicrob Agents Chemother. 2007 Sep;51(9):3397-400. doi: 10.1128/AAC.01242-06. Epub 2007 Jun 25.
4
Efficacy of linezolid in treatment of experimental endocarditis caused by methicillin-resistant Staphylococcus aureus.利奈唑胺治疗耐甲氧西林金黄色葡萄球菌所致实验性心内膜炎的疗效
Antimicrob Agents Chemother. 2001 Aug;45(8):2304-8. doi: 10.1128/AAC.45.8.2304-2308.2001.
5
Ceftobiprole is superior to vancomycin, daptomycin, and linezolid for treatment of experimental endocarditis in rabbits caused by methicillin-resistant Staphylococcus aureus.头孢洛林治疗耐甲氧西林金黄色葡萄球菌引起的兔实验性心内膜炎优于万古霉素、达托霉素和利奈唑胺。
Antimicrob Agents Chemother. 2010 Feb;54(2):610-3. doi: 10.1128/AAC.00886-09. Epub 2009 Nov 16.
6
Synergistic activity of ceftobiprole and vancomycin in a rat model of infective endocarditis caused by methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus.头孢洛林与万古霉素在耐甲氧西林和糖肽中介金黄色葡萄球菌致感染性心内膜炎大鼠模型中的协同作用。
Antimicrob Agents Chemother. 2012 Mar;56(3):1476-84. doi: 10.1128/AAC.06057-11. Epub 2012 Jan 9.
7
In-vitro profile of a new beta-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus.新型β-内酰胺类药物头孢比普对耐甲氧西林金黄色葡萄球菌的体外活性研究
Clin Microbiol Infect. 2007 Jun;13 Suppl 2:17-24. doi: 10.1111/j.1469-0691.2007.01722.x.
8
Successful treatment with moxifloxacin of experimental aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus (MRSA).莫西沙星成功治疗耐甲氧西林金黄色葡萄球菌（MRSA）所致的实验性主动脉瓣心内膜炎。
Int J Antimicrob Agents. 2009 Jan;33(1):65-9. doi: 10.1016/j.ijantimicag.2008.07.021. Epub 2008 Sep 24.
9
Therapeutic effect of ME1036 on endocarditis experimentally induced by methicillin-resistant Staphylococcus aureus.ME1036对耐甲氧西林金黄色葡萄球菌实验性诱导的心内膜炎的治疗效果。
Antimicrob Agents Chemother. 2005 Aug;49(8):3526-8. doi: 10.1128/AAC.49.8.3526-3528.2005.
引用本文的文献
1
New Antimicrobials and New Therapy Strategies for Endocarditis: Weapons That Should Be Defended.感染性心内膜炎的新型抗菌药物及新治疗策略：需加以捍卫的武器
J Clin Med. 2023 Dec 14;12(24):7693. doi: 10.3390/jcm12247693.
2
Ceftobiprole versus daptomycin in bacteremia: a novel protocol for a double-blind, Phase III trial.头孢洛林对比达托霉素治疗菌血症：一项双盲、III 期试验的新方案。
Future Microbiol. 2020 Jan;15(1):35-48. doi: 10.2217/fmb-2019-0332. Epub 2020 Jan 10.
3
Ceftobripole: Experience in staphylococcal bacteremia.头孢托罗培南：葡萄球菌血症的治疗经验。
Rev Esp Quimioter. 2019 Sep;32 Suppl 3(Suppl 3):24-28.
4
Comparative efficacies of tedizolid phosphate, vancomycin, and daptomycin in a rabbit model of methicillin-resistant Staphylococcus aureus endocarditis.磷酸特地唑胺、万古霉素和达托霉素在耐甲氧西林金黄色葡萄球菌心内膜炎兔模型中的疗效比较
Antimicrob Agents Chemother. 2015;59(6):3252-6. doi: 10.1128/AAC.04376-14. Epub 2015 Mar 23.
5
A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia.头孢比普甲磺酸盐与头孢他啶加利奈唑胺治疗医院获得性肺炎的3期随机双盲对照试验
Clin Infect Dis. 2014 Jul 1;59(1):51-61. doi: 10.1093/cid/ciu219. Epub 2014 Apr 9.
6
Efficacy of ceftobiprole Medocaril against Enterococcus faecalis in a murine urinary tract infection model.头孢洛林酯 Medocaril 对粪肠球菌引起的小鼠尿路感染模型的疗效。
Antimicrob Agents Chemother. 2012 Jun;56(6):3457-60. doi: 10.1128/AAC.06102-11. Epub 2012 Mar 26.
7
Synergistic activity of ceftobiprole and vancomycin in a rat model of infective endocarditis caused by methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus.头孢洛林与万古霉素在耐甲氧西林和糖肽中介金黄色葡萄球菌致感染性心内膜炎大鼠模型中的协同作用。
Antimicrob Agents Chemother. 2012 Mar;56(3):1476-84. doi: 10.1128/AAC.06057-11. Epub 2012 Jan 9.
8
Evaluation of ceftobiprole activity against a variety of gram-negative pathogens, including Escherichia coli, Haemophilus influenzae (β-lactamase positive and β-lactamase negative), and Klebsiella pneumoniae, in a rabbit meningitis model.评估头孢洛林在兔脑膜炎模型中对多种革兰氏阴性病原体（包括大肠杆菌、流感嗜血杆菌（β-内酰胺酶阳性和β-内酰胺酶阴性）和肺炎克雷伯菌）的活性。
Antimicrob Agents Chemother. 2012 Feb;56(2):921-5. doi: 10.1128/AAC.01537-10. Epub 2011 Nov 7.
9
In vivo synergism of ceftobiprole and vancomycin against experimental endocarditis due to vancomycin-intermediate Staphylococcus aureus.头孢洛林与万古霉素治疗耐万古霉素中间葡萄球菌实验性心内膜炎的体内协同作用。
Antimicrob Agents Chemother. 2011 Sep;55(9):3977-84. doi: 10.1128/AAC.00402-11. Epub 2011 Jul 5.
10
Emerging agents to combat complicated and resistant infections: focus on ceftobiprole.用于治疗复杂和耐药感染的新型药物：重点关注头孢洛林。
Infect Drug Resist. 2010;3:5-14. doi: 10.2147/idr.s3681. Epub 2010 Apr 22.
本文引用的文献
1
In vitro activities of a novel cephalosporin, CB-181963 (CAB-175), against methicillin-susceptible or -resistant Staphylococcus aureus and glycopeptide-intermediate susceptible staphylococci.新型头孢菌素CB-181963（CAB-175）对甲氧西林敏感或耐药金黄色葡萄球菌以及糖肽类中介敏感葡萄球菌的体外活性
Antimicrob Agents Chemother. 2004 Jul;48(7):2719-23. doi: 10.1128/AAC.48.7.2719-2723.2004.
2
Multiple-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers.新型广谱头孢菌素（BAL5788）在健康志愿者中的多剂量药代动力学及安全性研究
Antimicrob Agents Chemother. 2004 Jul;48(7):2576-80. doi: 10.1128/AAC.48.7.2576-2580.2004.
3
Single-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers.新型广谱头孢菌素（BAL5788）在健康志愿者中的单剂量药代动力学及安全性
Antimicrob Agents Chemother. 2004 Jul;48(7):2570-5. doi: 10.1128/AAC.48.7.2570-2575.2004.
4
Efficacy of BAL5788, a prodrug of cephalosporin BAL9141, in a mouse model of acute pneumococcal pneumonia.头孢菌素BAL9141的前体药物BAL5788在急性肺炎球菌肺炎小鼠模型中的疗效。
Antimicrob Agents Chemother. 2004 Apr;48(4):1105-11. doi: 10.1128/AAC.48.4.1105-1111.2004.
5
PBP 2a mutations producing very-high-level resistance to beta-lactams.产生对β-内酰胺类抗生素极高水平耐药性的PBP 2a突变。
Antimicrob Agents Chemother. 2004 Feb;48(2):453-9. doi: 10.1128/AAC.48.2.453-459.2004.
6
Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center.在好时医疗中心分离出的一株耐万古霉素金黄色葡萄球菌的抗菌药敏性。
J Antimicrob Chemother. 2003 Nov;52(5):864-8. doi: 10.1093/jac/dkg457. Epub 2003 Oct 16.
7
Structural basis for the beta lactam resistance of PBP2a from methicillin-resistant Staphylococcus aureus.耐甲氧西林金黄色葡萄球菌PBP2a对β-内酰胺耐药的结构基础
Nat Struct Biol. 2002 Nov;9(11):870-6. doi: 10.1038/nsb858.
8
In vitro and in vivo activities of a novel cephalosporin, BMS-247243, against methicillin-resistant and -susceptible staphylococci.新型头孢菌素BMS-247243对耐甲氧西林和甲氧西林敏感葡萄球菌的体外及体内活性
Antimicrob Agents Chemother. 2002 Apr;46(4):971-6. doi: 10.1128/AAC.46.4.971-976.2002.
9
In vitro activity of cephalosporin RWJ-54428 (MC-02479) against multidrug-resistant gram-positive cocci.头孢菌素RWJ-54428（MC-02479）对多重耐药革兰氏阳性球菌的体外活性。
Antimicrob Agents Chemother. 2002 Feb;46(2):321-6. doi: 10.1128/AAC.46.2.321-326.2002.
10
BAL9141, a novel extended-spectrum cephalosporin active against methicillin-resistant Staphylococcus aureus in treatment of experimental endocarditis.BAL9141，一种新型广谱头孢菌素，对耐甲氧西林金黄色葡萄球菌具有活性，用于治疗实验性心内膜炎。
Antimicrob Agents Chemother. 2002 Jan;46(1):171-7. doi: 10.1128/AAC.46.1.171-177.2002.
Zotero 插件